Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Company Overview

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Key Stats

• Today's Range: $4.00 to $4.14
• 50-Day Range: $3.87 to $5.01
• 52-Week Range: $3.40 to $11.00
• Volume: 336,794 shs
• Average Volume: 411,594 shs
• Market Capitalization: $72.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.00
• Consensus Rating: Buy

Unicycive Therapeutics Stock Analysis - MarketRank™

Unicycive Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 616th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Unicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Unicycive Therapeutics has a consensus price target of $57.00, representing about 1,293.6% upside from its current price of $4.09.

Amount of Analyst Coverage

Unicycive Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Unicycive Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Unicycive Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Unicycive Therapeutics has a P/B Ratio of 5.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.94% of the float of Unicycive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unicycive Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Unicycive Therapeutics does not currently pay a dividend.

Dividend Growth

Unicycive Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.94% of the float of Unicycive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unicycive Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.12

News Sentiment

Unicycive Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Unicycive Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 9 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.71% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

UNCY Stock Analysis - Frequently Asked Questions

How have UNCY shares performed this year?

Unicycive Therapeutics' stock was trading at $7.9420 on January 1st, 2025. Since then, UNCY shares have decreased by 48.5% and is now trading at $4.09.

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.18.

When did Unicycive Therapeutics' stock split?

Shares of Unicycive Therapeutics reverse split before market open on Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Unicycive Therapeutics IPO?

Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

Who are Unicycive Therapeutics' major shareholders?

Unicycive Therapeutics' top institutional investors include Vivo Capital LLC (9.00%), Octagon Capital Advisors LP (7.91%), Nantahala Capital Management LLC (7.43%) and Acuta Capital Partners LLC (0.50%).
View institutional ownership trends.

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Unicycive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UNCY
• CIK: 1766140
• Web: www.unicycive.com
• Phone: 650-351-4495
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Unicycive Therapeutics: $57.00
• High Price Target: $90.00
• Low Price Target: $21.00
• Potential Upside/Downside: +1,293.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -243.13%
• Return on Assets: -119.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.18
• Quick Ratio: 2.18

Sales & Book Value

• Annual Sales: $680 thousand
• Price / Sales: 106.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 5.68

Miscellaneous

• Outstanding Shares: 17,660,000
• Free Float: 15,770,000
• Market Cap: $72.23 million
• Optionable: Not Optionable
• Beta: 1.87